Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors

Gaitonde P, Chirikov V, Kelkar S, Liljas B

Cancer Management and Research 2022, 14:3421-3435

Published Date: 7 December 2022